News FDA Clears Integration Between LifeScan’s OneTouch Verio Flex® Blood Glucose Monitoring System and WellDoc’s BlueStar® Diabetes Management Platform

News FDA Clears Integration Between LifeScan’s OneTouch Verio Flex® Blood Glucose Monitoring System and WellDoc’s BlueStar® Diabetes Management Platform

December 14, 2016

December 14, 2016, Chesterbrook, PA – LifeScan, Inc., part of the Johnson & Johnson Diabetes Care Companies and a world leader in blood glucose monitoring, today announced the U.S. Food and Drug Administration (FDA) has cleared the wireless integration of the OneTouch Verio Flex® blood glucose monitoring system with WellDoc Inc.’s clinically validated diabetes management platform, BlueStar® , creating a unique digital health solution for people living with Type 2 diabetes.

In today’s world, access to care anywhere is more important than ever. Digital health is quickly becoming the new normal. Join us for a discussion on how digital health technologies are working to bring care to all patients.